Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * *
* *

 NEWS  1            Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2            "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27    New STN AnaVist pricing effective March 1, 2006
 NEWS  4  APR 04    STN AnaVist $500 visualization usage credit offered
 NEWS  5  MAY 10    CA/CAplus enhanced with 1900-1906 U.S. patent
records
 NEWS  6  MAY 11    KOREAPAT updates resume
 NEWS  7  MAY 19    Derwent World Patents Index to be reloaded and
enhanced
 NEWS  8  MAY 30    IPC 8 Rolled-up Core codes added to CA/CAplus and
                    USPATFULL/USPAT2
 NEWS  9  MAY 30    The F-Term thesaurus is now available in CA/CAplus
 NEWS 10  JUN 02    The first reclassification of IPC codes now
complete in
                    INPADOC
 NEWS 11  JUN 26    TULSA/TULSA2 reloaded and enhanced with new search
and
                    and display fields
 NEWS 12  JUN 28    Price changes in full-text patent databases EPFULL
and PCTFULL
 NEWS 13  JUl 11    CHEMSAFE reloaded and enhanced
 NEWS 14  JUl 14    FSTA enhanced with Japanese patents
 NEWS 15  JUl 19    Coverage of Research Disclosure reinstated in DWPI
 NEWS 16  AUG 09    INSPEC enhanced with 1898-1968 archive

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
```

```
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation
of IPC 8
 NEWS X25       X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *
* *

FILE 'HOME' ENTERED AT 14:45:50 ON 10 AUG 2006

=> file reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:46:05 ON 10 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     9 AUG 2006  HIGHEST RN 900096-56-2
DICTIONARY FILE UPDATES:    9 AUG 2006  HIGHEST RN 900096-56-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:
```

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10501689.str





chain nodes :
11 12 13 14 16 17 19 20 22
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-19 3-22 4-20 7-13 8-11 11-12 11-17 13-14 13-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-19 3-22 4-20 5-7 6-9 7-8 7-13 8-9 8-11 11-12 11-17 13-14
13-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:O,S

G2:C,H,Ak

G3:H,OH,CN,X,Ak,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom
9:Atom 11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:CLASS 17:Atom
19:CLASS 20:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 14:46:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 639 TO ITERATE

100.0% PROCESSED 639 ITERATIONS 28
ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 11264 TO 14296
PROJECTED ANSWERS: 243 TO 877

L2 28 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:46:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 12649 TO ITERATE

100.0% PROCESSED 12649 ITERATIONS 567
ANSWERS
SEARCH TIME: 00.00.01

L3 567 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 166.94 167.15

FILE 'CAPLUS' ENTERED AT 14:46:45 ON 10 AUG 2006

FILE COVERS 1907 - 10 Aug 2006 VOL 145 ISS 7
FILE LAST UPDATED: 9 Aug 2006 (20060809/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 12 L3

=> d l4 ibib hitstr abs 1-12

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:588929 CAPLUS
DOCUMENT NUMBER: 143:115430
TITLE: Preparation of aroylfurans and aroylthiophenes for
treating neoplastic and autoimmune diseases
INVENTOR(S): Eberle, Martin; Bachmann, Felix; Strebel, Alessandro;
Roy, Subho; Saha, Goutam; Sadhukhan, Subir Kumar;
Saxena, Rohit; Srivastava, Sudhir
PATENT ASSIGNEE(S): Aponetics A.-G., Switz.
SOURCE: PCT Int. Appl., 180 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061476	A2	20050707	WO 2004-EP53622	20041221
WO 2005061476	A3	20060126		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2545821	AA	20050707	CA 2004-2545821	20041221

PRIORITY APPLN. INFO.:

EP 2003-405911	A 20031222
EP 2003-405912	A 20031222
EP 2004-405517	A 20040819
WO 2004-EP53622	W 20041221

OTHER SOURCE(S): MARPAT 143:115430

IT 857841-76-0P 857842-15-0P 857842-16-1P
857842-17-2P 857842-18-3P 857842-19-4P
857842-20-7P 857842-21-8P 857842-22-9P
857842-23-0P 857842-24-1P 857842-26-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of aroylfurans and aroylthiophenes for treating neoplastic and
autoimmune diseases)
RN 857841-76-0 CAPLUS
CN Methanone, (3-amino-5-chloro-2-benzofuranyl)[2-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 857842-15-0 CAPLUS
CN Methanone,
(3-amino-5-chloro-2-benzofuranyl)[2-(ethylamino)-3-pyridinyl]-
(9CI) (CA INDEX NAME)



RN 857842-16-1 CAPLUS
CN Methanone, (3-amino-5-chloro-2-benzofuranyl)[2-(dimethylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 857842-17-2 CAPLUS
CN Methanone,
(3-amino-5-chloro-2-benzofuranyl)(2-ethoxy-3-pyridinyl)- (9CI)
(CA INDEX NAME)



RN 857842-18-3 CAPLUS
CN Methanone,
(3-amino-5-chloro-2-benzofuranyl)[2-(1-pyrrolidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 857842-19-4 CAPLUS
CN Methanone,
(3-amino-5-chloro-2-benzofuranyl)[2-(ethylmethylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 857842-20-7 CAPLUS
CN Methanone,
(3-amino-5-chloro-2-benzofuranyl)[2-(diethylamino)-3-pyridinyl]-
(9CI) (CA INDEX NAME)



RN 857842-21-8 CAPLUS
CN Methanone, (3-amino-5-chloro-2-benzofuranyl)[2-(1-piperidinyl)-3-
pyridinyl]- (9CI) (CA INDEX NAME)



RN 857842-22-9 CAPLUS
CN Methanone, (3-amino-5-chloro-2-benzofuranyl)[2-(2,6-dimethyl-4-
morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 857842-23-0 CAPLUS
CN Methanone,
(3-amino-5-chloro-2-benzofuranyl)[2-(hexahydro-1H-1,4-diazepin-1-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 857842-24-1 CAPLUS
CN Methanone,
(3-amino-5-chloro-2-benzofuranyl)[2-(4-methyl-1-piperazinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 857842-26-3 CAPLUS
CN Methanone,
(3-amino-5-chloro-2-benzofuranyl)[2-(4-hydroxy-1-piperidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



IT 857841-65-7P 857842-90-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of aroylfurans and aroylthiophenes for treating neoplastic and
autoimmune diseases)
RN 857841-65-7 CAPLUS
CN Methanone,
(3-amino-5-chloro-2-benzofuranyl)(2-chloro-3-pyridinyl)- (9CI)
(CA INDEX NAME)



RN 857842-90-1 CAPLUS
CN Methanone,
(3-amino-5-chloro-2-benzofuranyl)(2-bromo-3-pyridinyl)- (9CI)
(CA INDEX NAME)



GI



I



II



III

AB The invention relates to compds. I and II [ring A = = Ph, pyridine,
pyrimidine or pyrazine ring; W and X = C, N; Y = O, S; R0 = alkoxymethyl,
cyclohexyl, Ph, etc.; Rx = C(O)R1 or cyano; R1 = H, (un)substituted OH or
(un)substituted NH2; R6 = H, alkyl, haloalkyl, etc.; R8 = H, alkyl,
alkoxy, halo]. The invention further relates to methods of synthesis of
compds. I and II, to pharmaceutical compns. containing compds. I and II, to
the use of such compds. for the preparation of a pharmaceutical composition for the
treatment of neoplastic and autoimmune diseases, and to methods of
treatment of neoplastic and autoimmune diseases using compds. I and II or
of pharmaceutical compns. containing same. E.g., a multi-step synthesis of
III, starting from 2-benzyloxyacetophenone, was given. The exemplified

compds. I and II were tested in various cell lines (data given).

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:502640 CAPLUS
DOCUMENT NUMBER: 143:172703
TITLE: Synthesis and conversion of 3-(2-hydroxythiobenzamido)benzo[b]furans
AUTHOR(S): Briel, Detlef
CORPORATE SOURCE: Institute of Pharmacy, Faculty of Biosciences, Pharmacy, and Psychology, University of Leipzig, Leipzig, D-04103, Germany
SOURCE: Heterocycles (2005), 65(6), 1295-1309
CODEN: HTCYAM; ISSN: 0385-5414
PUBLISHER: Japan Institute of Heterocyclic Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:172703
IT 860801-63-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of [(hydroxy)thiobenzamido]benzo[b]furan derivs. via
O-alkylation, ring transformation and oxygen-sulfur exchange sequence
using [(hydroxy)phenyl]-1,2,4-dithiazol-ylidene]-cyclohexadienone and
acyl bromides as starting materials)
RN 860801-63-4 CAPLUS
CN Benzenecarbothioamide, 2-hydroxy-N-[2-(2-thienylcarbonyl)-3-benzofuranyl]-
(9CI) (CA INDEX NAME)



AB A simple method for the introduction of a 2-aroyl-3-benzofuranyl residue at the nitrogen atom of 2-hydroxy-thiobenzamide is described. Thereby N-(2-aroyl-3-benzofuranyl)-2-hydroxy-thiobenzamides were obtained which undergo an oxygen-sulfur position exchange when they were heated in acetic acid yielding the isomeric N-(2-thioaroyl-3-benzofuranyl)-2-hydroxy-benzamide derivs.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:260074 CAPLUS
DOCUMENT NUMBER: 142:316835
TITLE: Preparation of thienopyrazoles as inhibitors of interleukin-2 inducible tyrosine kinase for treating diseases involving overproduction of Th2 cytokine like asthma
INVENTOR(S): Jurcak, John Gerard; Barrague, Matthieu; Gillespy, Timothy Alan; Edwards, Michael Louis; Musick, Kwon Yon; Weintraub, Philip Marvin; Du, Yan; Dharanipragada, Ramalinga M.; Parkar, Ashfaq Ahmed
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005026175	A1	20050324	WO 2004-US23814	20040723

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004272507	A1	20050324	AU 2004-272507	20040723
CA 2538032	AA	20050324	CA 2004-2538032	20040723
EP 1682553	A1	20060726	EP 2004-779049	20040723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
NO 2006001626	A	20060410	NO 2006-1626	20060410
PRIORITY APPLN. INFO.:			US 2003-501159P	P 20030908
			WO 2004-US23814	W 20040723

OTHER SOURCE(S): MARPAT 142:316835

IT 848357-66-4P, [3-(2-Benzhydrylidenehydrazino)benzo[b]thiophen-2-yl][1-(benzyloxymethyl)-6-[3-(piperidin-1-yl)propoxy]-1H-benzimidazol-2-yl]methanone

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thienopyrazoles as inhibitors of interleukin-2 inducible

tyrosine kinase for treating diseases involving overprodn. of Th2
cytokine like asthma)
RN 848357-66-4 CAPLUS
CN Methanone, diphenyl-, [2-[[1-[(phenylmethoxy)methyl]-6-[3-(1-piperidinyl)propoxy]-1H-benzimidazol-2-yl]carbonyl]benzo[b]thien-3-yl]hydrazone (9CI) (CA INDEX NAME)



GI



I

AB This invention relates to thienopyrazoles (shown as I; variables defined
below; e.g. 2-(1H-thieno[3,2-c]pyrazol-3-yl)-1H-benzimidazole), their
preparation, pharmaceutical compns. comprising these compds., and their
pharmaceutical uses in the treatment of disease states capable of being
modulated by the inhibition of the protein kinases, in particular

interleukin-2 inducible tyrosine kinase (ITK). IC50 values for inhibition of ITK and IL-4 release are tabulated for 26 examples of I. For I: X is N, or C-R7; X1 is N, or C-R1; R1, R2, R3, R4, R5 and R6 = H, or (un)substituted acyl, alkyl, alkoxy, acylamino, alkenyl, alkoxyalkyl, or (Y1)(Y2)NC(O)-, (Y1)(Y2)N-, or alkoxycarbonyl, alkylsulfinyl, alkylsulfonyl, alkylsulfonylcarbamoyl, alkylthio, alkynyl, aroyl, aryl, aroylamino, arylalkyl, arylalkoxy, arylalkyloxyalkyl, arylalkyloxycarbonyl, aryloxyalkyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylsulfonylcarbamoyl, arylthio, cycloalkenyl, cycloalkoxyalkyl, cycloalkyl, cycloalkylalkyl, cycloalkyloxy, heteroaroyl, heteroaroylamino, heteroarylalkyl, heteroarylalkoxy, heteroarylalkyloxyalkyl, heteroaryloxy, heteroaryloxyalkyl, heterocycloalkyl, heteroarylsulfonylcarbamoyl, heterocycloalkylalkyl, heterocycloalkyloxy, heterocycloalkyloxyalkyl, or halo, hydroxy, trifluoromethyl, nitro, (un)substituted hydroxyalkyl, carboxy, or cyano; or R5 and R6, together with the two double-bonded carbons to which they are attached, form an (un)substituted benzene ring. R7 is H, halo or (un)substituted alkyl; and Y1 and Y2 = H, (un)substituted alkyl, (un)substituted aryl, or (un)substituted heteroaryl, or Y1 and Y2, together with the N to which they are attached form an (un)substituted heteroaryl group, or an (un)substituted heterocycloalkyl group. Although the methods of preparation are not claimed, >70 example prepns. are included.

For example, 2-(1H-thieno[3,2-c]pyrazol-3-yl)-1H-benzimidazole was prepared in 5 steps starting from 3-bromothiophene-2-carboxylic acid and involving intermediates 3-bromothiophene-2-carboxylic acid N-methoxy-N-methylamide, 1-(benzyloxymethyl)-1H-benzimidazole, [1-(benzyloxymethyl)-1H-benzimidazol-2-yl](3-bromothiophen-2-yl)methanone and [3-(2-

benzhydrylidenehydrazino)thiophen-2-yl][1-(benzyloxymethyl)-1H-benzimidazol-2-yl]methanone.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:696882 CAPLUS
DOCUMENT NUMBER: 139:230615
TITLE: Preparation of benzofurans and benzothiophenes useful in the treatment of hyperproliferative disorders
INVENTOR(S): Zhang, Chengzhi; Burke, Michael; Chen, Zhi; Dumas, Jacques; Fan, Dongping; Fan, Jianmei; Hatoum-Mokdad, Holia; Jones, Benjamin D.; Ladouceur, Gaetan; Lee, Wendy; Phillips, Barton
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072561	A1	20030904	WO 2003-US5396	20030221

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2474511 AA 20030904 CA 2003-2474511 20030221
AU 2003213219 A1 20030909 AU 2003-213219 20030221
EP 1487813 A1 20041222 EP 2003-709265 20030221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
CN 1639146 A 20050713 CN 2003-804436 20030221
CN 1639145 A 20050713 CN 2003-804442 20030221
JP 2006507215 T2 20060302 JP 2003-571267 20030221
BR 2003007905 A 20060404 BR 2003-7905 20030221
ZA 2004007482 A 20050919 ZA 2004-7482 20040917
NO 2004003952 A 20041022 NO 2004-3952 20040921
PRIORITY APPLN. INFO.: US 2002-359011P P 20020222
US 2002-399886P P 20020731
WO 2003-US5396 W 20030221
OTHER SOURCE(S): MARPAT 139:230615
IT 594811-07-1P 594811-12-8P 594811-21-9P
594811-31-1P 594811-43-5P 594811-48-0P
594811-49-1P 594811-50-4P 594811-53-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(antitumor agent; preparation of benzofurans and benzothiophenes for
treatment of hyper-proliferative disorders)
RN 594811-07-1 CAPLUS

CN Methanone, (3-amino-6-phenyl-2-benzofuranyl)[4-(1-methylethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 594811-12-8 CAPLUS
CN Methanone,
[3-amino-6-(4-methyl-3-thienyl)-2-benzofuranyl]-1,3-benzodioxol-4-yl- (9CI) (CA INDEX NAME)



RN 594811-21-9 CAPLUS
CN Methanone,
[3-amino-6-(4-methoxyphenyl)-2-benzofuranyl](4-methyl-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 594811-31-1 CAPLUS
CN Methanone,
[3-amino-6-(3-fluorophenyl)-2-benzofuranyl](4-methyl-3-

pyridinyl)- (9CI) (CA INDEX NAME)



RN 594811-43-5 CAPLUS
CN Methanone,
[3-amino-6-(3-aminophenyl)-2-benzofuranyl][4-(trifluoromethyl)-
3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 594811-48-0 CAPLUS
CN Methanone,
[3-amino-6-(3-furanyl)-2-benzofuranyl][4-(trifluoromethyl)-3-
pyridinyl]- (9CI) (CA INDEX NAME)



RN 594811-49-1 CAPLUS
CN Methanone,
[3-amino-6-(2-thienyl)-2-benzofuranyl][4-(trifluoromethyl)-3-
pyridinyl]- (9CI) (CA INDEX NAME)



RN 594811-50-4 CAPLUS
CN Methanone,
[3-amino-6-(3-thienyl)-2-benzofuranyl][4-(trifluoromethyl)-3-
pyridinyl]- (9CI) (CA INDEX NAME)



RN 594811-53-7 CAPLUS
CN Methanone, [3-amino-6-(3-nitrophenyl)-2-benzofuranyl](2-methyl-3-
pyridinyl)- (9CI) (CA INDEX NAME)



IT 594812-60-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation);
USES
(Uses)
(preparation of benzofurans and benzothiophenes for treatment
of
hyper-proliferative disorders)

RN 594812-60-9 CAPLUS
CN Methanone,
[3-amino-6-(1H-pyrrol-1-yl)-2-benzofuranyl]-1,3-benzodioxol-4-
yl- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X = O, S; R1 = H, alkyl, (CO)alkyl, benzoyl; R2 =
(un)substituted Ph, naphthyl, (un)substituted heterocyclyl; R3 = H, OH,
CN, alkyl, alkoxy, halo, haloalkyl, haloalkoxy; R4 = piperonyl,
(un)substituted heterocyclyl, Ph and naphthyl; R5, R6 = independently H,
OH, CN, alkyl, alkoxy, halo, haloalkyl and haloalkoxy; and their
pharmaceutically acceptable salts or esters] were prepared as antitumor
agents for treatment of hyperproliferative disorders. For example, II was
prepared from 2-bromo-3'-methoxy-acetophenone by cyclocondensation with
acetamide at 110° for 40 h, demethylation in DCM at room temperature for
2 h, reaction with paraformaldehyde in CH3CN/TEA in the presence of MgCl2
at reflux for 17 h, reaction with nitroethane in AcOH/AcONa at reflux for
17 h, and K2CO3-catalyzed cyclocondensation of the resultant nitrile with

2-methoxyphenacyl bromide in anhydrous DMF. III was prepared, in 28.2% yield,
by Pd-cross coupling of (3-amino-6-iodo-1-benzothiophene-2-yl)(2,4-dichlorophenyl)methanone with pyridine-3-boronic acid in 1,2-dimethoxyethane at 80° for 18 h. I showed a significant inhibition of tumor cell proliferation in the adherent tumor cell proliferation assay (no data). Thus, I and their formulations are useful
as antitumor agents (no data).
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:824243 CAPLUS
DOCUMENT NUMBER: 134:4854
TITLE: Preparation of oligohydroxyl substituted benzofuranylurea derivatives as phosphodiesterase IV inhibitors
INVENTOR(S): Braunlich, Gabriele; Es-Sayed, Mazen; Fischer, Rudiger; Fugmann, Burkhard; Henning, Rolf; Schneider, Stephan; Sperzel, Michael; Schlemmer, KarlHeinz; Sturton, Graham; Fitzgerald, Mary; Briggs, Barbara; Concepcion, Arnel; Bullock, William
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069844	A1	20001123	WO 2000-EP4016	20000504

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,

CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

GB 2350111 A1 20001122 GB 1999-11456 19990517
PRIORITY APPLN. INFO.: GB 1999-11456 A 19990517
OTHER SOURCE(S): MARPAT 134:4854

IT 308340-26-3P 308340-27-4P 308340-38-7P
308340-48-9P 308340-49-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oligohydroxyl substituted benzofuranylurea derivs. as
phosphodiesterase IV inhibitors)

RN 308340-26-3 CAPLUS

CN Urea,
[6-(2,3-dihydroxypropoxy)-2-[(2,6-dimethyl-3-pyridinyl)carbonyl]-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 308340-27-4 CAPLUS
CN Urea,
[6-[2,3-dihydroxy-2-(hydroxymethyl)propoxy]-2-[(2,6-dimethyl-3-pyridinyl)carbonyl]-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 308340-38-7 CAPLUS
CN Urea,
[2-[(2,6-dimethyl-3-pyridinyl)carbonyl]-6-[3-fluoro-2-hydroxy-2-(hydroxymethyl)propoxy]-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 308340-48-9 CAPLUS
CN Urea,
[2-[(5-chloro-2-thienyl)carbonyl]-6-(2,3-dihydroxypropoxy)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 308340-49-0 CAPLUS
CN Urea,
[2-[(2,5-dichloro-3-thienyl)carbonyl]-6-(2,3-dihydroxypropoxy)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



IT 308340-80-9P 308340-88-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of oligohydroxyl substituted benzofuranylurea derivs. as
phosphodiesterase IV inhibitors)
RN 308340-80-9 CAPLUS
CN Urea,
[2-[(2,6-dimethyl-3-pyridinyl)carbonyl]-6-hydroxy-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 308340-88-7 CAPLUS
CN Urea,
[2-[(5-chloro-2-thienyl)carbonyl]-6-(2-propenyloxy)-3-benzofuranyl]-
(9CI) (CA INDEX NAME)



GI



I

AB The title compds. I [A and D including the double bond connecting them
together form a phenyl-, pyridyl-, pyrimidyl, pyridazinyl-, pyrazinyl- or
thienyl-ring, which is substituted by a group of OR5; R5 = straight-chain
or branched alkyl having 1 to 15 carbon atoms, which is substituted difold

to fivefold by hydroxyl or di-fold to fivefold by straight-chain or branched alkoxy having 1 to 6 carbon atoms and wherein alkyl is optionally substituted by 20 straight-chain or branched alkoxycarbonyl having 1 to 6 carbon atoms, halo, carboxyl, (C3-C8)-cycloalkyl or by Ph, which is optionally substituted monofold to fivefold by nitro, halo or Ph; E = oxygen or sulfur; R2, R3 = H, cycloalkyl, alkyl, etc. or R2NR3 = heterocycle; R4 = aryl, heterocycle] were prepared and their use in medicaments for the treatment of inflammatory processes is reported.

E.g., 2-(2,4-dichlorobenzoyl)-6-(2,3-dihydroxy-1-propyloxy)-3-ureidobenzofuran was prepared

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:824241 CAPLUS
DOCUMENT NUMBER: 134:4852
TITLE: Preparation of benzofuranylsulfonates as antiinflammatory agents
INVENTOR(S): Braunlich, Gabriele; Es-Sayed, Mazen; Fischer, Rudiger; Fugmann, Burkhard; Henning, Rolf; Schneider, Stephan; Sperzel, Michael; Schlemmer, Karl-Heinz; Sturton, Graham; Fitzgerald, Mary; Briggs, Barbara; Concepcion, Arnel; Bullock, William
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2000069842 A1 20001123 WO 2000-EP4010
20000504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH,
CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,
SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,
BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
GB 2350109 A1 20001122 GB 1999-11452
19990517
CA 2373666 AA 20001123 CA 2000-2373666
20000504
EP 1187821 A1 20020320 EP 2000-931116
20000504
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,
IE, SI, LT, LV, FI, RO
JP 2002544270 T2 20021224 JP 2000-618259
20000504
US 6610687 B1 20030826 US 2002-979371
20020225
PRIORITY APPLN. INFO.: GB 1999-11452 A
19990517
WO 2000-EP4010 W
20000504
OTHER SOURCE(S): MARPAT 134:4852
IT 308285-79-2P 308285-80-5P 308285-81-6P
308285-82-7P 308285-83-8P 308285-84-9P
308285-85-0P 308285-86-1P 308285-87-2P
308285-88-3P 308285-89-4P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzofuranylsulfonates as antiinflammatory
agents)

RN 308285-79-2 CAPLUS
CN Urea,
[2-[(2,6-dimethyl-3-pyridinyl)carbonyl]-6-[(methylsulfonyl)oxy]-3-
benzofuranyl]- (9CI) (CA INDEX NAME)



RN 308285-80-5 CAPLUS
CN Benzenemethanesulfonic acid,
3-[(aminocarbonyl)amino]-2-[(2,6-dimethyl-3-
pyridinyl)carbonyl]-6-benzofuranyl ester (9CI) (CA INDEX NAME)



RN 308285-81-6 CAPLUS
CN 1H-Imidazole-4-sulfonic acid, 1-methyl-,
3-[(aminocarbonyl)amino]-2-[(2,6-
dimethyl-3-pyridinyl)carbonyl]-6-benzofuranyl ester (9CI) (CA INDEX NAME)



RN 308285-82-7 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-,
3-[(aminocarbonyl)amino]-2-[(2,6-dimethyl-3-pyridinyl)carbonyl]-6-benzofuranyl ester (9CI) (CA INDEX NAME)



RN 308285-83-8 CAPLUS
CN 2-Thiophenesulfonic acid, 5-(2-pyridinyl)-,
3-[(aminocarbonyl)amino]-2-
[(2,6-dimethyl-3-pyridinyl)carbonyl]-6-benzofuranyl ester (9CI)
(CA INDEX
NAME)



RN 308285-84-9 CAPLUS
CN 2-Thiophenesulfonic acid,
3-[(aminocarbonyl)amino]-2-[(2,6-dimethyl-3-
pyridinyl)carbonyl]-6-benzofuranyl ester (9CI) (CA INDEX NAME)



RN 308285-85-0 CAPLUS
CN 2-Naphthalenesulfonic acid, 5,6,7,8-tetrahydro-,
3-[(aminocarbonyl)amino]-
2-[(2,6-dimethyl-3-pyridinyl)carbonyl]-6-benzofuranyl ester
(9CI) (CA
INDEX NAME)



RN 308285-86-1 CAPLUS
CN 2-Propanesulfonic acid,
3-[(aminocarbonyl)amino]-2-[(2,6-dimethyl-3-
pyridinyl)carbonyl]-6-benzofuranyl ester (9CI) (CA INDEX NAME)



RN 308285-87-2 CAPLUS
CN 1-Propanesulfonic acid,
3-[(aminocarbonyl)amino]-2-[(2,6-dimethyl-3-
pyridinyl)carbonyl]-6-benzofuranyl ester (9CI) (CA INDEX NAME)



RN 308285-88-3 CAPLUS
CN Ethanesulfonic acid, 3-[(aminocarbonyl)amino]-2-[(2,6-dimethyl-3-pyridinyl)carbonyl]-6-benzofuranyl ester (9CI) (CA INDEX NAME)



RN 308285-89-4 CAPLUS
CN 2-Thiophenesulfonic acid, 5-chloro-, 3-[(aminocarbonyl)amino]-2-[(2,6-dimethyl-3-pyridinyl)carbonyl]-6-benzofuranyl ester (9CI) (CA INDEX NAME)



GI



I



II

AB The title compds. [I; A = H, acyl, alkoxycarbonyl, etc.; R1 = H, alkyl,
protecting group, etc.; R2, R3 = H, cycloalkyl, alkyl, etc.; NR2R3 = 5-7
membered saturated heterocycle optionally having a further O atom; R4 = aryl,

heterocyclyl; L = O, S; D = 1,2,3,4-tetrahydronaphthalen-6-yl, quinolin-8-yl, aryl, etc.] which inhibit the production of superoxide by polymorphonuclear leukocytes (PMN), and also inhibit TNFα release and potentiate IL-10 production in human monocytes, (biol.data such as IC50 against O2- formation and against PDE IV were given), were prepared E.g., a general procedure for preparation of benzofuranylsulfonates I such as II was presented.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:617912 CAPLUS
DOCUMENT NUMBER: 133:296336
TITLE: Synthesis and analgesic activity of some substituted 1-benzofurans and 1-benzothiophenes
AUTHOR(S): Radl, Stanislav; Hezky, Petr; Konvicka, Petr; Krejci, Ivan
CORPORATE SOURCE: Research Institute of Pharmacy and Biochemistry, Prague, 130 60/3, Czech Rep.
SOURCE: Collection of Czechoslovak Chemical Communications (2000), 65(7), 1093-1108
CODEN: CCCCAK; ISSN: 0010-0765
PUBLISHER: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:296336
IT 301538-67-0P 301538-69-2P 301538-70-5P 301538-71-6P 301538-72-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, acid-base equilibrium consts., and analgesic activity of

substituted aminobenzofurans and -benzothiophenes)
RN 301538-67-0 CAPLUS
CN Methanone, (3-amino-2-benzofuranyl)-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 301538-69-2 CAPLUS
CN Methanone, (3-amino-2-benzofuranyl)-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 301538-70-5 CAPLUS
CN Methanone, (3-aminobenzo[b]thien-2-yl)-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 301538-71-6 CAPLUS
CN Methanone, (3-aminobenzo[b]thien-2-yl)-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 301538-72-7 CAPLUS
CN Methanone, (3-aminobenzo[b]thien-2-yl)-4-pyridinyl- (9CI) (CA INDEX NAME)



IT 301538-68-1P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation, acid-base equilibrium consts., and analgesic activity of
substituted aminobenzofurans and -benzothiophenes)
RN 301538-68-1 CAPLUS
CN Methanone, (3-amino-2-benzofuranyl)-3-pyridinyl- (9CI) (CA INDEX NAME)



AB 2-Benzoyl- and 2-(pyridylcarbonyl)benzofuran-3-amines were prepared from
2-hydroxybenzonitrile and corresponding bromoethanones. 2-Benzoyl- and
2-(pyridylcarbonyl)benzothiophene-3-amines were prepared analogously from

2-mercaptobenzonitrile. 2-Benzoylbenzofuran-3-amine treated with acetic anhydride or Et chloroformate provided the corresponding N-acetyl or N-ethoxycarbonyl derivs. These N-activated compds. were alkylated with Et bromoacetate to provide Et N-acetyl-N-(2-benzoylbenzofuran-3-yl)glycinate and Et N-(2-benzoylbenzofuran-3-yl)-N-ethoxycarbonylglycinate, resp. Their mild hydrolysis gave the corresponding glycine derivs. Methylation of Et N-(2-benzoylbenzofuran-3-yl)carbamate gave the corresponding N-Me carbamate, which was hydrolyzed to N-methyl-(2-benzoylbenzofuran-3-yl)amine. 2-Benzoyl-7-methoxybenzofuran-3-amine and 2-(4-methoxybenzoyl)benzofuran-3-amine were demethylated with boron tribromide to the corresponding hydroxy derivs.; their O-alkylation with Et bromoacetate gave Et [(3-amino-2-benzoylbenzofuran-7-yl)oxy]acetate and Et {4-[(3-aminobenzofuran-2-yl)carbonyl]phenoxy}acetate, resp. The mild hydrolysis of these esters provided corresponding acids. Similarly, alkylation of the hydroxy derivs. with (dimethylamino)propyl chloride gave corresponding (dimethylamino)propoxy derivs. 2-Hydroxybenzonitrile treated with 2-bromopyridyl ethan-1-ones provided corresponding 2-(pyridylcarbonyl)benzofuran-3-amines. 2-(Pyridylcarbonyl)benzothiophene-3-amines were prepared analogously from 2-mercaptobenzonitrile. 2-Benzoyl-3-(bromomethyl)benzofuran treated with dimethylamine, 1-methylpiperazine, and sodium 1-methylpiperidine-4-thiolate gave the corresponding alkylation products. Several compds. were found to exhibit considerable analgesic activity. However, their activity was not so significant to justify their further development as analgesic agents.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:510149 CAPLUS
DOCUMENT NUMBER: 127:121637
TITLE: Preparation of heterocyclylcarbonyl-substituted benzofuranylureas as antiinflammatories.
INVENTOR(S): Braeunlich, Gabriele; Es-sayed, Mazen; Fischer, Ruediger; Fugmann, Burkhardt; Henning, Rolf; Sperzel, Michael; Nielsch, Ulrich; Sturton, Graham
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Eur. Pat. Appl., 30 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 779291	A1	19970618	EP 1996-119046	19961128
EP 779291	B1	20011010		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 206709	E	20011015	AT 1996-119046	19961128
ES 2161955	T3	20011216	ES 1996-119046	19961128
PT 779291	T	20020228	PT 1996-119046	19961128
US 5922740	A	19990713	US 1996-760612	19961204
CA 2192281	AA	19970612	CA 1996-2192281	19961206
JP 09202785	A2	19970805	JP 1996-340388	19961206
PRIORITY APPLN. INFO.:			GB 1995-25262 A	19951211

OTHER SOURCE(S): MARPAT 127:121637
IT 192574-42-8P 192574-43-9P 192574-44-0P
192574-45-1P 192574-46-2P 192574-47-3P

192574-48-4P 192574-49-5P 192574-50-8P
192574-51-9P 192574-52-0P 192574-53-1P
192574-54-2P 192574-55-3P 192574-56-4P
192574-57-5P 192574-58-6P 192574-59-7P
192574-60-0P 192574-61-1P 192574-63-3P
192574-64-4P 192574-65-5P 192574-66-6P
192574-67-7P 192574-68-8P 192574-69-9P
192574-70-2P 192574-71-3P 192574-72-4P
192574-73-5P 192574-74-6P 192574-75-7P
192574-76-8P 192574-77-9P 192574-78-0P
192574-79-1P 192574-80-4P 192574-81-5P
192574-82-6P 192574-83-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylcarbonyl-substituted benzofuranylureas as
antiinflammatories)
RN 192574-42-8 CAPLUS
CN Urea, [5-methoxy-2-(3-pyridinylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX
NAME)



RN 192574-43-9 CAPLUS
CN Urea, [6-methoxy-2-(4-pyridinylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX
NAME)



RN 192574-44-0 CAPLUS
CN Urea, [6-methoxy-2-(3-pyridinylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 192574-45-1 CAPLUS
CN Urea, [6-methoxy-2-(pyrazinylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 192574-46-2 CAPLUS
CN Urea, [6-methoxy-2-(2-pyridinylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX

NAME)



RN 192574-47-3 CAPLUS
CN Urea, [5-methoxy-2-(4-pyridinylcarbonyl)-3-benzofuranyl]- (9CI)
(CA INDEX
NAME)



RN 192574-48-4 CAPLUS
CN Urea, [6-methoxy-2-(2-thienylcarbonyl)-3-benzofuranyl]- (9CI)
(CA INDEX
NAME)



RN 192574-49-5 CAPLUS
CN Urea, [5-methoxy-2-(2-thienylcarbonyl)-3-benzofuranyl]- (9CI)
(CA INDEX
NAME)



RN 192574-50-8 CAPLUS
CN Urea,
[5-chloro-6-methoxy-2-(3-pyridinylcarbonyl)-3-benzofuranyl]- (9CI)
(CA INDEX NAME)



RN 192574-51-9 CAPLUS
CN Pyridinium, 2-[[3-[(aminocarbonyl)amino]-6-methoxy-2-benzofuranyl]carbonyl]-1-methyl-, iodide (9CI) (CA INDEX NAME)



● I^-

RN 192574-52-0 CAPLUS
CN Pyridinium, 4-[[3-[(aminocarbonyl)amino]-6-methoxy-2-benzofuranyl]carbonyl]-1-ethyl-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 192574-53-1 CAPLUS
CN Pyridinium, 4-[[3-[(aminocarbonyl)amino]-6-methoxy-2-benzofuranyl]carbonyl]-1-methyl-, iodide (9CI) (CA INDEX NAME)



● I^-

RN 192574-54-2 CAPLUS
CN Pyridinium, 3-[[3-[(aminocarbonyl)amino]-6-methoxy-2-benzofuranyl]carbonyl]-1-methyl-, iodide (9CI) (CA INDEX NAME)



● I^-

RN 192574-55-3 CAPLUS
CN Urea, [6-methyl-2-(3-pyridinylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 192574-56-4 CAPLUS
CN Urea, [6-methyl-2-(4-pyridinylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 192574-57-5 CAPLUS
CN Pyridinium, 4-[[3-[(aminocarbonyl)amino]-6-methoxy-2-benzofuranyl]carbonyl]-1-(2-methoxy-2-oxoethyl)-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 192574-58-6 CAPLUS
CN Pyridinium, 3-[[3-[(aminocarbonyl)amino]-6-methoxy-2-benzofuranyl]carbonyl]-1-ethyl-, iodide (9CI) (CA INDEX NAME)



● I^-

RN 192574-59-7 CAPLUS
CN Urea, [6-methoxy-2-(2-thiazolylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 192574-60-0 CAPLUS
CN Urea, [5-methoxy-2-(3-thienylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 192574-61-1 CAPLUS
CN Urea, [6-methoxy-2-[(5-methyl-2-furanyl)carbonyl]-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 192574-63-3 CAPLUS
CN Urea, [2-(3-pyridinylcarbonyl)-6-(trifluoromethyl)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 192574-64-4 CAPLUS
CN Urea,
[2-[(5-bromo-3-pyridinyl)carbonyl]-6-methoxy-3-benzofuranyl]- (9CI)
(CA INDEX NAME)



RN 192574-65-5 CAPLUS
CN Urea, [5-fluoro-6-nitro-2-(3-pyridinylcarbonyl)-3-benzofuranyl]-
(9CI)
(CA INDEX NAME)



RN 192574-66-6 CAPLUS
CN Carbamic acid, [[[5-methoxy-2-(2-pyridinylcarbonyl)-3-benzofuranyl]amino]thioxomethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 192574-67-7 CAPLUS
CN Carbamic acid, [[[6-methoxy-2-(2-pyridinylcarbonyl)-3-benzofuranyl]amino]thioxomethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 192574-68-8 CAPLUS
CN Urea,
[2-[(2,6-dimethyl-3-pyridinyl)carbonyl]-6-methoxy-3-benzofuranyl]-
(9CI) (CA INDEX NAME)



RN 192574-69-9 CAPLUS
CN Urea,
[2-[(5-chloro-2-thienyl)carbonyl]-6-methoxy-3-benzofuranyl]- (9CI)
(CA INDEX NAME)



RN 192574-70-2 CAPLUS
CN Pyridinium,
1-[(acetyloxy)methyl]-3-[[3-[(aminocarbonyl)amino]-6-methoxy-2-

benzofuranyl]carbonyl]-, chloride (9CI) (CA INDEX NAME)



● Cl^-

RN 192574-71-3 CAPLUS
CN Urea,
[2-[(2,5-dichloro-3-thienyl)carbonyl]-6-methoxy-3-benzofuranyl]-
(9CI) (CA INDEX NAME)



RN 192574-72-4 CAPLUS
CN Urea,
[2-[(3,4-dibromo-2-thienyl)carbonyl]-6-methoxy-3-benzofuranyl]-
(9CI) (CA INDEX NAME)



RN 192574-73-5 CAPLUS
CN Urea,
[2-[(5-bromo-2-thienyl)carbonyl]-6-methoxy-3-benzofuranyl]- (9CI)
(CA INDEX NAME)



RN 192574-74-6 CAPLUS
CN Urea,
[2-[(3-bromo-2-thienyl)carbonyl]-6-methoxy-3-benzofuranyl]- (9CI)
(CA INDEX NAME)



RN 192574-75-7 CAPLUS

CN Urea, [6-cyano-2-(2-thienylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 192574-76-8 CAPLUS
CN Urea, [2-[(5-chloro-2-thienyl)carbonyl]-6-nitro-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 192574-77-9 CAPLUS
CN Urea, [6-nitro-2-(2-thienylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 192574-78-0 CAPLUS
CN Urea, [2-[(3,5-dichloro-2-pyridinyl)carbonyl]-6-methoxy-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 192574-79-1 CAPLUS
CN Urea,
[2-[(2,5-dimethyl-3-thienyl)carbonyl]-6-methoxy-3-benzofuranyl]-
(9CI) (CA INDEX NAME)



RN 192574-80-4 CAPLUS
CN Urea,
[2-[(3-cyano-2-thienyl)carbonyl]-6-methoxy-3-benzofuranyl]- (9CI)
(CA INDEX NAME)



RN 192574-81-5 CAPLUS
CN Urea, [6-nitro-2-[(5-nitro-3-thienyl)carbonyl]-3-benzofuranyl]-
(9CI) (CA

INDEX NAME)



RN 192574-82-6 CAPLUS
CN Urea, [2-[(5-chloro-2-thienyl)carbonyl]-6-cyano-3-benzofuranyl]- (9CI)
(CA INDEX NAME)



RN 192574-83-7 CAPLUS
CN Urea, [2-[(2,5-dichloro-3-thienyl)carbonyl]-6-(2-propenyloxy)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



IT 192574-84-8P 192574-85-9P 192574-86-0P
192574-87-1P 192574-88-2P 192574-89-3P
192574-90-6P 192574-91-7P 192574-92-8P
192574-93-9P 192574-94-0P 192574-95-1P
192574-96-2P 192574-97-3P 192574-98-4P
192574-99-5P 192575-00-1P 192575-01-2P
192575-02-3P 192575-03-4P 192575-04-5P
192575-05-6P 192575-06-7P 192575-07-8P

192575-08-9P 192575-09-0P 192575-10-3P
192575-11-4P 192575-12-5P 192575-13-6P
192575-14-7P 192575-15-8P 192575-16-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of heterocyclylcarbonyl-substituted benzofuranylureas as
antiinflammatories)
RN 192574-84-8 CAPLUS
CN Methanone, (3-amino-5-methoxy-2-benzofuranyl)-3-pyridinyl- (9CI) (CA
INDEX NAME)



RN 192574-85-9 CAPLUS
CN Methanone, (3-amino-6-methoxy-2-benzofuranyl)-4-pyridinyl- (9CI) (CA
INDEX NAME)



RN 192574-86-0 CAPLUS
CN Methanone, (3-amino-6-methoxy-2-benzofuranyl)-3-pyridinyl- (9CI) (CA
INDEX NAME)



RN 192574-87-1 CAPLUS
CN Methanone, (3-amino-6-methoxy-2-benzofuranyl)pyrazinyl- (9CI) (CA INDEX NAME)



RN 192574-88-2 CAPLUS
CN Methanone, (3-amino-6-methoxy-2-benzofuranyl)-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 192574-89-3 CAPLUS
CN Methanone, (3-amino-5-chloro-6-methoxy-2-benzofuranyl)-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 192574-90-6 CAPLUS
CN Methanone, (3-amino-5-chloro-6-methoxy-2-benzofuranyl)-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 192574-91-7 CAPLUS
CN Methanone, (3-amino-5-methoxy-2-benzofuranyl)-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 192574-92-8 CAPLUS
CN Methanone, (3-amino-6-methoxy-2-benzofuranyl)-2-thienyl- (9CI) (CA INDEX NAME)



RN 192574-93-9 CAPLUS
CN Methanone, (3-amino-5-methoxy-2-benzofuranyl)-2-pyridinyl- (9CI) (CA
INDEX NAME)



RN 192574-94-0 CAPLUS
CN Methanone, (3-amino-6-methyl-2-benzofuranyl)-3-pyridinyl- (9CI) (CA INDEX
NAME)



RN 192574-95-1 CAPLUS
CN Methanone, (3-amino-6-methyl-2-benzofuranyl)-4-pyridinyl- (9CI) (CA INDEX
NAME)



RN 192574-96-2 CAPLUS
CN Methanone, (3-amino-6-methoxy-2-benzofuranyl)-2-thiazolyl- (9CI) (CA
INDEX NAME)



RN 192574-97-3 CAPLUS
CN Methanone, (3-amino-5-methoxy-2-benzofuranyl)-3-thienyl- (9CI) (CA INDEX
NAME)



RN 192574-98-4 CAPLUS
CN Methanone,
(3-amino-6-methoxy-2-benzofuranyl)(5-bromo-3-pyridinyl)- (9CI)
(CA INDEX NAME)



RN 192574-99-5 CAPLUS
CN Methanone,
(3-amino-6-methoxy-2-benzofuranyl)(5-methyl-2-furanyl)- (9CI)
(CA INDEX NAME)



RN 192575-00-1 CAPLUS
CN Methanone,
[3-amino-6-(trifluoromethyl)-2-benzofuranyl]-3-pyridinyl- (9CI)
(CA INDEX NAME)



RN 192575-01-2 CAPLUS
CN Methanone,
(3-amino-5-fluoro-6-nitro-2-benzofuranyl)-3-pyridinyl- (9CI)
(CA INDEX NAME)



RN 192575-02-3 CAPLUS
CN Methanone,
(3-amino-6-methoxy-2-benzofuranyl)(5-chloro-2-thienyl)- (9CI)
(CA INDEX NAME)



RN 192575-03-4 CAPLUS
CN Methanone,
(3-amino-6-methoxy-2-benzofuranyl)(2,6-dimethyl-3-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 192575-04-5 CAPLUS
CN Methanone,
(3-amino-6-methoxy-2-benzofuranyl)(2,5-dichloro-3-thienyl)-
(9CI) (CA INDEX NAME)



RN 192575-05-6 CAPLUS
CN Methanone,
(3-amino-6-methoxy-2-benzofuranyl)(3,4-dibromo-2-thienyl)-
(9CI) (CA INDEX NAME)



RN 192575-06-7 CAPLUS
CN Methanone,
(3-amino-6-methoxy-2-benzofuranyl)(3-bromo-2-thienyl)- (9CI)
(CA INDEX NAME)



RN 192575-07-8 CAPLUS
CN Methanone,
(3-amino-6-methoxy-2-benzofuranyl)(5-bromo-2-thienyl)- (9CI)
(CA INDEX NAME)



RN 192575-08-9 CAPLUS
CN Methanone,
(3-amino-6-methoxy-2-benzofuranyl)[2,2'-bipyridin]-6-yl- (9CI)
(CA INDEX NAME)



RN 192575-09-0 CAPLUS
CN Methanone,
(3-amino-6-methoxy-2-benzofuranyl)(2-chloro-4-pyridinyl)- (9CI)
(CA INDEX NAME)



RN 192575-10-3 CAPLUS
CN 6-Benzofurancarbonitrile, 3-amino-2-(2-thienylcarbonyl)- (9CI)
(CA INDEX NAME)



RN 192575-11-4 CAPLUS
CN Methanone, (3-amino-6-nitro-2-benzofuranyl)(5-chloro-2-thienyl)-
(9CI)
(CA INDEX NAME)



RN 192575-12-5 CAPLUS
CN Methanone, (3-amino-6-nitro-2-benzofuranyl)-2-thienyl- (9CI)
(CA INDEX
NAME)



RN 192575-13-6 CAPLUS
CN Methanone,
(3-amino-6-methoxy-2-benzofuranyl)(2,5-dimethyl-3-thienyl)-
(9CI) (CA INDEX NAME)



102

RN 192575-14-7 CAPLUS
CN Methanone,
(3-amino-6-methoxy-2-benzofuranyl)(5-methyl-3-thienyl)- (9CI)
(CA INDEX NAME)



102

RN 192575-15-8 CAPLUS
CN 2-Thiophenecarbonitrile,
4-[(3-amino-6-methoxy-2-benzofuranyl)carbonyl]-
(9CI) (CA INDEX NAME)



102

RN 192575-16-9 CAPLUS
CN Methanone,
(3-amino-6-methoxy-2-benzofuranyl)(3,5-dichloro-2-pyridinyl)-
(9CI) (CA INDEX NAME)



GI



I

AB Title compds. [I; A, D = H, acyl, alkoxycarbonyl, halo, CO2H, cyano, NO2,
CF3, OCF3, etc.; R1 = H, alkyl, protecting group, acyl; R2, R3 = H,
cycloalkyl, alkyl, alkoxycarbonyl, alkenyl, (substituted) PhCO, aryl;
R2R3N = heterocyclyl; R4 = (unsatd.) (substituted) (benzanellated)
heterocyclyl; L = O, S], were prepared Thus, (3-amino-5-methoxybenzofuran-2-
yl)piperidin-3-ylmethanone (preparation given) in CH2Cl2 was treated with
chlorosulfonyl isocyanate at 0° followed by stirring for 4 h at
room temperature to give 17% [5-methoxy-2-(pyridin-3-carbonyl)benzofuran-3-
yl]urea. I inhibited FMLP-stimulated production of superoxide radical anions
with IC50 = 0.07-10 μM.

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:175080 CAPLUS
DOCUMENT NUMBER: 126:171488
TITLE: Preparation of benzofuro[3,2-b]pyridines as endothelin

receptor antagonists

INVENTOR(S): Osswald, Mathias; Dorsch, Dieter; Mederski, Werner;
Wilm, Claudia; Schmitges, Claus;
Christadler, Maria
PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany
SOURCE: Eur. Pat. Appl., 70 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 755934	A1	19970129	EP 1996-111677	19960719
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 19527568	A1	19970130	DE 1995-19527568	19950728
AU 9660607	A1	19970206	AU 1996-60607	19960719
CA 2182156	AA	19970129	CA 1996-2182156	19960726
NO 9603131	A	19970129	NO 1996-3131	19960726
JP 09040678	A2	19970210	JP 1996-214052	19960726
ZA 9606399	A	19970219	ZA 1996-6399	19960726
US 5700807	A	19971223	US 1996-687922	19960726
BR 9603164	A	19980505	BR 1996-3164	19960726

PRIORITY APPLN. INFO.: DE 1995-19527568 A 19950728
OTHER SOURCE(S): MARPAT 126:171488
IT 187154-67-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of benzofuro[3,2-b]pyridines as endothelin receptor
antagonists)

RN 187154-67-2 CAPLUS
CN Methanone,
(3-amino-2-benzofuranyl)(2,3-dihydro-1,4-benzodioxin-6-yl)-
(9CI) (CA INDEX NAME)



GI



I



II



III

AB The title compds. [I; R1 = Ar (wherein Ar = (un)substituted Ph, naphthyl, etc.); R2 = COOH, COOC1-6 alkyl, CN, etc.; R3-R5 = halo, NO2, CN, etc.; X = O, S; Y-Z = NR7C(O), N:C(OR7), N:CR8 (wherein R7 = CH2Ar, CH2CH2Ar, etc.; R8 = Ar, ArO)], useful for the prophylaxis and/or therapy of cardiac, circulatory and vascular illnesses, especially hypertension and cardiac insufficiency, were prepared and formulated. Thus, reaction of 50% solution of 2-methoxybenzyl chloride in CH2Cl2 with Et 4-(1,4-benzodioxan-6-yl)-1,2-dihydro-2-oxobenzofuro[3,2-b]pyridine-3-carboxylate in DMF in the presence of Cs2CO3 afforded II and III. Compds. I are effective at 0.02-10 mg/kg/day.

L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:265421 CAPLUS
DOCUMENT NUMBER: 122:81257
TITLE: Synthesis and reactions of 2-substituted 4H-benzofuro[3,2-d]-m-oxazin-4-ones
AUTHOR(S): Harwalkar, G. S.; Agasimundin, Y. S.
CORPORATE SOURCE: Department Chemistry, Gulbarga University, Gulbarga, 585 106, India
SOURCE: Indian Journal of Heterocyclic Chemistry (1994), 3(4), 247-52
CODEN: IJCHEI; ISSN: 0971-1627
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 160461-38-1P 160461-39-2P 160461-40-5P
160461-41-6P 160461-42-7P 160461-43-8P
160461-44-9P 160461-45-0P 160461-46-1P
160461-47-2P 160461-48-3P 160461-49-4P
160461-50-7P 160461-51-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 160461-38-1 CAPLUS
CN Acetamide, N-[2-(1-piperidinylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 160461-39-2 CAPLUS
CN Propanamide, N-[2-(1-piperidinylcarbonyl)-3-benzofuranyl]- (9CI) (CA
INDEX NAME)



RN 160461-40-5 CAPLUS
CN Benzeneacetamide, N-[2-(1-piperidinylcarbonyl)-3-benzofuranyl]- (9CI) (CA
INDEX NAME)



RN 160461-41-6 CAPLUS
CN Benzamide, N-[2-(1-piperidinylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX
NAME)



RN 160461-42-7 CAPLUS
CN Benzamide,
4-methyl-N-[2-(1-piperidinylcarbonyl)-3-benzofuranyl]- (9CI)
(CA INDEX NAME)



RN 160461-43-8 CAPLUS
CN Benzamide,
4-methoxy-N-[2-(1-piperidinylcarbonyl)-3-benzofuranyl]- (9CI)
(CA INDEX NAME)



RN 160461-44-9 CAPLUS
CN Benzamide,
4-chloro-N-[2-(1-piperidinylcarbonyl)-3-benzofuranyl]- (9CI)
(CA INDEX NAME)



RN 160461-45-0 CAPLUS
CN Acetamide, N-[2-(4-morpholinylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 160461-46-1 CAPLUS
CN Propanamide, N-[2-(4-morpholinylcarbonyl)-3-benzofuranyl]- (9CI) (CA INDEX NAME)



RN 160461-47-2 CAPLUS
CN Benzeneacetamide, N-[2-(4-morpholinylcarbonyl)-3-benzofuranyl]- (9CI) (CA

INDEX NAME)



RN 160461-48-3 CAPLUS
CN Benzamide, N-[2-(4-morpholinylcarbonyl)-3-benzofuranyl]- (9CI)
(CA INDEX
NAME)



RN 160461-49-4 CAPLUS
CN Benzamide,
4-methyl-N-[2-(4-morpholinylcarbonyl)-3-benzofuranyl]- (9CI)
(CA INDEX NAME)



RN 160461-50-7 CAPLUS
CN Benzamide,
4-methoxy-N-[2-(4-morpholinylcarbonyl)-3-benzofuranyl]- (9CI)
(CA INDEX NAME)



RN 160461-51-8 CAPLUS
CN Benzamide,
4-chloro-N-[2-(4-morpholinylcarbonyl)-3-benzofuranyl]- (9CI)
(CA INDEX NAME)



GI



I

AB Title compds. I [R = Me, Et, CH2Ph, (un)substituted Ph] were prepared, and their reactions with aliphatic and aromatic amines were investigated. The selectivity of the reaction pathway was shown to depend on steric factors.

L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:591598 CAPLUS
DOCUMENT NUMBER: 101:191598
TITLE: The conversions of isothiazolium salts into thiophenecarboxylic ester derivatives
AUTHOR(S): McKinnon, David M.; Duncan, K. Ann; Millar, Lesley M.
CORPORATE SOURCE: Dep. Chem., Univ. Manitoba, Winnipeg, MB, R3T 2N2, Can.
SOURCE: Canadian Journal of Chemistry (1984), 62(8), 1580-4
CODEN: CJCHAG; ISSN: 0008-4042
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 101:191598
IT 92802-05-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 92802-05-6 CAPLUS
CN Pyrrolidine,
1-[[3-[(phenylmethyl)amino]benzo[b]thien-2-yl]carbonyl]-
(9CI) (CA INDEX NAME)



GI



ClO_4^- I

AB Several 3-aminothiophene-2-carboxylic ester derivs. were prepared by
reaction of EtO2CCH2CO2K or Me2S:CHCO2Et with isothiazolium perchlorates I
(e.g., R = R3 = Ph, R1 = R2 = H). In the latter case deaminated products
were also isolated. These products were consistent with initial
nucleophilic attack on the S atom of the isothiazolium salt. In one case
a pyrrole derivative formed by a novel rearrangement of an intermediate
aziridine derivative Some further derivs. of 3-(benzylamino)benzo[b]thiophene
were described.

L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:71816 CAPLUS
DOCUMENT NUMBER: 78:71816
TITLE: New synthesis of 3-amino-2-cylbenzo[b]thiophenes
AUTHOR(S): Boeshagen, Horst; Geiger, Walter
CORPORATE SOURCE: Forschungslab., Bayer A. G., Wuppertal-Elberfeld, Fed. Rep. Ger.
SOURCE: Justus Liebigs Annalen der Chemie (1972), 764, 58-68
CODEN: JLACBF; ISSN: 0075-4617

DOCUMENT TYPE: Journal
LANGUAGE: German
IT 40239-88-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40239-88-1 CAPLUS
CN Methanone, [3-(ethylamino)benzo[b]thien-2-yl]-2-thienyl- (9CI)
(CA INDEX
NAME)



GI For diagram(s), see printed CA Issue.
AB Thirteen title compds. (I, R = Me, Et, Ph, C6H4Me-o, C6H4F-p, C6H4Cl-m, or
CH2CH:CH2; R1 = Me, 2-thienyl, Ph, C6H4NO2-m, CMe3, or CHMe2; R2 = H or
Cl) were prepared in 60-80% yield by reaction of the benzisothiazole (II)
with MeCOR1. I were desulfurized with Raney Ni to give
cis-s-cis-p-R2C6H4C(NHR):CHCOR1. Reaction of I (R = Ph, R1 = Me, R2 = H)
with Ac2O, H2NNHSO2Ph, or H2NNH2 gave the N-acetyl derivative of I, the
phenylsulfonylhydrazone of I, or the azine of I, resp. Oxidation of I with
perphthalic acid gave the S,S-dioxides.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	61.78	228.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.00	-9.00

STN INTERNATIONAL LOGOFF AT 14:47:26 ON 10 AUG 2006